COMMUNIQUÉS West-GlobeNewswire

Major shareholder announcement
23/06/2025
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and [...]
Sharecare wins 21 Digital Health Awards in Spring 2025 competition
23/06/2025
Company earns Gold for its NCQA-accredited health navigation platform for large employers and commercial health plans, immersive medical animation, and doctor-patient communications support ATLANTA, June 23, 2025 (GLOBE [...]
Transactions under Novonesis’ share buyback program
23/06/2025
As of June 20th, 2025, Novonesis has purchased an accumulated 1,660,344 shares with a transaction value of DKK 713,0 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and [...]
TOMI Environmental Solutions Demonstrates SteraMist Efficacy in Combatting Honeybee Colony Collapse
23/06/2025
FREDERICK, Md., June 23, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced significant [...]
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
23/06/2025
REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a [...]
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
23/06/2025
REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and [...]
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)
23/06/2025
New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on promising imaging data [...]
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
23/06/2025
- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ( [...]
New DoseSpot Analysis of 100,000 GLP-1 Prescriptions Finds That Patients Overpaid by $10.2M Collectively
23/06/2025
92 percent of prescriptions could have been filled at a lower price, with better information on pricing, dispensing options and manufacturer cost-savings programs BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- DoseSpot , [...]
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
23/06/2025
Basel, June 23, 2025 – Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously [...]
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
23/06/2025
Ad hoc announcement pursuant to Art. 53 LR Idorsia to receive USD 50 million (an additional USD 30 million) approval milestone payment in return for a reduction in Simcere potential sales milestones and tiered royalty [...]
Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe
23/06/2025
Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe Recommandation fondée sur l’étude de phase 3 GMMG-HD7 [...]
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
23/06/2025
Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment [...]
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
23/06/2025
Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the highest dose groups in people with haemophilia [...]
SBC Medical Participated in 4 Investor Conferences in May and June 2025
23/06/2025
IRVINE, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, recently participated in [...]
Galapagos Appoints Aaron Cox as Chief Financial Officer
23/06/2025
Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – [...]
Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors
23/06/2025
MUTTENZ, Switzerland, June 23, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a Swiss-based life sciences company developing a next-generation, non-glucose based peritoneal dialysis (PD) solution, today announced the [...]
AB Science - De nouvelles données évaluées par des pairs apportent des preuves solides du potentiel du masitinib dans le traitement de la maladie d’Alzheimer
23/06/2025
COMMUNIQUE DE PRESSE DE NOUVELLES DONNÉES ÉVALUÉES PAR DES PAIRS APPORTENT DES PREUVES SOLIDES DU POTENTIEL DU MASITINIB DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER GRÂCE À UN DOUBLE MÉCANISME D'AMÉLIORATION COGNITIVE [...]
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
23/06/2025
PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION THIS [...]

Pages